147 related articles for article (PubMed ID: 36371187)
21. Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer.
Geng Y; Chen X; Qiu J; Zhou Y; Wang J; Liu L; Shao Y; Yin Y
Int J Clin Oncol; 2014 Apr; 19(2):303-11. PubMed ID: 23660785
[TBL] [Abstract][Full Text] [Related]
22. Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment.
Hedner C; Borg D; Nodin B; Karnevi E; Jirström K; Eberhard J
J Clin Pathol; 2018 May; 71(5):451-462. PubMed ID: 29138285
[TBL] [Abstract][Full Text] [Related]
23. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
[TBL] [Abstract][Full Text] [Related]
24. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer.
Ren X; Song Y; Zhang Y; Wu H; Chen L; Pang J; Zhou L; Shen S; Liang Z
BMC Cancer; 2022 May; 22(1):548. PubMed ID: 35568835
[TBL] [Abstract][Full Text] [Related]
26. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.
Terashima M; Kitada K; Ochiai A; Ichikawa W; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H; Sasako M;
Clin Cancer Res; 2012 Nov; 18(21):5992-6000. PubMed ID: 22977193
[TBL] [Abstract][Full Text] [Related]
27. HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.
Cherifi F; Da Silva A; Johnson A; Blanc-Fournier C; Abramovici O; Broyelle A; Levy C; Allouache D; Hrab I; Segura C; Morel A; Villemin M; Boscher C; Dubot-Poitelon C; Rottier P; Lequesne J; Emile G
BMC Cancer; 2022 Oct; 22(1):1081. PubMed ID: 36266623
[TBL] [Abstract][Full Text] [Related]
28. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
Frogne T; Laenkholm AV; Lyng MB; Henriksen KL; Lykkesfeldt AE
Breast Cancer Res; 2009; 11(1):R11. PubMed ID: 19239686
[TBL] [Abstract][Full Text] [Related]
29. The Role of Human Epidermal Growth Factor Receptor (HER2/neu) in the Prognosis of Patients with Gastric Cancer.
Aznab M; Maleksabet D; Khazaei S; Khazaei M; Rezaei M
Asian Pac J Cancer Prev; 2019 Jul; 20(7):1989-1994. PubMed ID: 31350955
[TBL] [Abstract][Full Text] [Related]
30. Prognosis of HER2 over-expressing gastric cancer patients with liver metastasis.
Dang HZ; Yu Y; Jiao SC
World J Gastroenterol; 2012 May; 18(19):2402-7. PubMed ID: 22654433
[TBL] [Abstract][Full Text] [Related]
31. Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer.
Wu Y; Han Y; Li Q; Zhang P; Yuan P; Luo Y; Fan Y; Chen S; Cai R; Li Q; Xu H; Wang Y; Ma F; Wang J; Xu B
Breast Cancer Res Treat; 2022 Jun; 193(2):381-392. PubMed ID: 35297009
[TBL] [Abstract][Full Text] [Related]
32. Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer.
Chen M; Wu J; Liu D; Chen W; Lin C; Andriani L; Ding S; Huang O; He J; Chen X; Chen W; Li Y; Shen K; Zhu L
Clin Breast Cancer; 2022 Feb; 22(2):e147-e156. PubMed ID: 34244052
[TBL] [Abstract][Full Text] [Related]
33. The Prognostic Value of the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging System in HER2-Enriched Subtype Breast Cancer, a Retrospective Analysis.
Zhou B; Xu L; Ye J; Xin L; Duan X; Liu Y
Anticancer Res; 2017 Aug; 37(8):4615-4621. PubMed ID: 28739761
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of circulating tumor cells in the response to trastuzumab for HER2-negative metastatic gastric cancer.
Matsushita D; Uenosono Y; Arigami T; Yanagita S; Okubo K; Kijima T; Miyazono F; Hamanoue M; Hokita S; Nakashima S; Ohtsuka T; Natsugoe S
Cancer Chemother Pharmacol; 2021 Jun; 87(6):789-797. PubMed ID: 33641065
[TBL] [Abstract][Full Text] [Related]
35. An independent survival prognostic role for human epidermal growth factor receptor 2 in gastric cancer: evidence from a meta-analysis.
Wang Y; He L; Cheng Y
Clin Transl Oncol; 2018 Feb; 20(2):212-220. PubMed ID: 28681313
[TBL] [Abstract][Full Text] [Related]
36. Expression and significance of Her2 and Ki-67 in gastric adenocarcinoma without distant metastasis: a cohort study.
Wei Z; Huang L; Zhang X; Xu A
BMC Gastroenterol; 2020 Oct; 20(1):343. PubMed ID: 33059614
[TBL] [Abstract][Full Text] [Related]
37. HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance.
Sheng WQ; Huang D; Ying JM; Lu N; Wu HM; Liu YH; Liu JP; Bu H; Zhou XY; Du X
Ann Oncol; 2013 Sep; 24(9):2360-4. PubMed ID: 23788757
[TBL] [Abstract][Full Text] [Related]
38. A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status.
Bria E; De Manzoni G; Beghelli S; Tomezzoli A; Barbi S; Di Gregorio C; Scardoni M; Amato E; Frizziero M; Sperduti I; Corbo V; Brunelli M; Bersani S; Tortora G; Scarpa A
Ann Oncol; 2013 Mar; 24(3):693-701. PubMed ID: 23131390
[TBL] [Abstract][Full Text] [Related]
39. Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis.
Chen C; Yang JM; Hu TT; Xu TJ; Yan G; Hu SL; Wei W; Xu WP
Arch Med Res; 2013 Jul; 44(5):380-9. PubMed ID: 23871709
[TBL] [Abstract][Full Text] [Related]
40. Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment.
Yoon SH; Kim YH; Lee YJ; Park J; Kim JW; Lee HS; Kim B
PLoS One; 2016; 11(8):e0161278. PubMed ID: 27517841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
